SLC9B2

Sodium/hydrogen exchanger 9B2 · Q86UD5 · SLC9B2 on Sugi Atlas →

536 patent compounds predicted against SLC9B2, 484 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Phloretin (SCHEMBL38131)	1.00	1/20
Phloretin (SCHEMBL1506325)	1.00	1/20
Phloretin (SCHEMBL30785809)	0.96	1/20
Phloretin (SCHEMBL30912872)	0.96	1/20
Phloretin (SCHEMBL31684375)	0.96	1/20
Phloretin (SCHEMBL27910960)	0.93	1/20
Phloretin (SCHEMBL6402644)	0.87	1/20
Phloretin (SCHEMBL21192491)	0.87	1/20
Phloretin (SCHEMBL27817019)	0.87	1/20
Phloretin (SCHEMBL27889444)	0.87	1/20
Phloretin (SCHEMBL27906064)	0.87	1/20
Phloretin (SCHEMBL28362318)	0.87	1/20
Phloretin (SCHEMBL30603791)	0.87	1/20
Phloretin (SCHEMBL11343841)	0.82	1/20
SCHEMBL28895928	0.81	1/20
Phloretin (SCHEMBL9347996)	0.79	1/20
Phloretin (SCHEMBL30099878)	0.79	1/20
SCHEMBL454232	0.78	1/20
SCHEMBL455620	0.78	1/20
SCHEMBL457501	0.78	1/20

Clinical trials — most relevant to SLC9B2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure	PHASE4	RECRUITING
Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study	PHASE4	RECRUITING
Salt Loading and Thiazide Intervention Study	PHASE4	COMPLETED
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)	PHASE4	COMPLETED
Secretin in Ex-situ Liver Perfusion	PHASE1/PHASE2	ENROLLING_BY_INVITATION
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops	PHASE2	UNKNOWN
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin	PHASE2	NOT_YET_RECRUITING
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Gene Expression in Inflammatory Bowel Disease	nan	ENROLLING_BY_INVITATION
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS	nan	NOT_YET_RECRUITING
Bile Acids Metabolism and Genetic Mutation Profile in the Intrahepatic Cholestasis of Pregnacy in Indian Population	nan	RECRUITING
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital	nan	UNKNOWN
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Autonomic Function in Patients With COPD	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS	nan	COMPLETED
Sodium Transport: Genetics and Hypertension	nan	COMPLETED
Blood Pressure Control in Juveniles - Longitudinal Study	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Clinical Phenotypic Characteristics of SC26A4	nan	UNKNOWN
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease	nan	COMPLETED
Central Sodium Sensing: Implications for Blood Pressure Regulation	nan	COMPLETED
Genetic Variants and Iron Absorption	nan	COMPLETED
New Biomarkers and Difficult-to-treat Hypertension	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC9B2 binder may also engage these)

Protein	Name	Similarity
Q5R6B8	—	1.000	Q5R6B8 →
A0A6P3HVI0	—	0.993	A0A6P3HVI0 →
Q5BKR2	—	0.988	Q5BKR2 →
A4IHB9	—	0.980	A4IHB9 →
O35874	—	0.957	O35874 →
Q5R839	—	0.956	Q5R839 →
Q8IVJ1	—	0.956	Q8IVJ1 →
P49282	—	0.955	P49282 →
A2VDL4	—	0.953	A2VDL4 →
Q8BJA2	—	0.952	Q8BJA2 →
F7B113	—	0.952	F7B113 →
SLC10A2	Ileal sodium/bile acid cotransporter	0.952	landscape →
A0A2K2BF92	—	0.952	A0A2K2BF92 →
D4A7H1	—	0.952	D4A7H1 →
B9H7I1	—	0.951	B9H7I1 →
E7EXX2	—	0.951	E7EXX2 →
Q60414	—	0.951	Q60414 →
SLC11A2	Natural resistance-associated macrophage protein 2	0.950	landscape →
O54902	—	0.950	O54902 →
SLC1A3	Excitatory amino acid transporter 1	0.949	landscape →
P43007	—	0.949	P43007 →
P46411	—	0.948	P46411 →
Q8IVB4	—	0.948	Q8IVB4 →
Q8R070	—	0.947	Q8R070 →
P24942	—	0.947	P24942 →
Q28727	—	0.947	Q28727 →
P57057	—	0.946	P57057 →
Q62633	—	0.946	Q62633 →
Q9SAH8	—	0.946	Q9SAH8 →
Q5M7K3	—	0.946	Q5M7K3 →